IN THE CLAIMS:

Please cancel claim 44 without prejudice or disclaimer.

In accordance with 37 C.F.R. § 1.121(c)(1), please substitute for claims 24 and 41, the following rewritten version of the same claim, as amended. The changes are shown explicitly in the attached "Version with Markings to Show Changes Made."

24. (Amended) A method of treating a tumor, comprising administering to a human patient a radiolabeled peptide and a pharmaceutically acceptable carrier,

wherein said radiolabeled peptide is prepared by contacting a solution of a peptide with stannous ions, wherein said peptide comprises a radiometal-binding moiety comprising the structure:



wherein R^1, R^2, and R^3 independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, and a protecting group that can be removed under the conditions of peptide synthesis, provided that at least one of R^1, R^2, or R^3 is H,

R^5, R^7, R^8, R^9 and R^{10} independently are selected from the group consisting of H, lower alkyl, substituted lower alkyl, aryl, and substituted aryl, and R^8 and R^9 together or R^7 and R^9 together may form a cycloalkyl or substituted cycloalkyl ring,

R^4 and R^6 together form a direct bond or are independently selected from the group consisting of lower alkyl, substituted lower alkyl, aryl, and substituted aryl, and wherein NR^{10} is located at the N-terminus of said peptide, or is located on an amino acid side chain of said peptide,

and then contacting said solution with a radionuclide and recovering the

C2 cont. radiolabeled peptide.

41. (Amended) A method according to claim 24, wherein said peptide is selected from the group consisting of:

(Chel)γAbuNleDHF$_d$ RWK-NH$_2$, (SEQ ID NO:1)

(Chel)γAbuHSDAVFTDNYTRLRKQMAVKKYLNSILN-NH$_2$, (SEQ ID NO:2)

KPRRPYTDNYTRLRK(Chel)QMAVKKYLNSILN-NH$_2$, (SEQ ID NO:3)

(Chel)γAbuVFTDNYTRLRKQMAVKKYLNSILN-NH$_2$,

C3 (Chel)γAbuYTRLRKQMAVKKYLNSILN-NH$_2$, (SEQ ID NO:4)

HSDAVFTDNYTRLRK(Chel)QMAVKKYLNSILN-NH$_2$, (SEQ ID NO:5)

(SEQ ID NO:6) <GHWSYK(Chel)LRPG-NH$_2$, <GHYSLK(Chel)WKPG-NH$_2$, (SEQ ID NO:7)

AcNal$_d$ Cpa$_d$ W$_d$ SRK$_d$ (Chel)LRPA$_d$ -NH$_2$, (SEQ ID NO:8)

(SEQ ID NO:9) (Chel)γAbuSYSNleDHF$_d$ RWK-NH$_2$, Ac-HSDAVFTENYTKLRK(Chel)QNleAAKKYLNDLKKGGT-NH$_2$, (SEQ ID NO:10)

(SEQ ID NO:12) Nal$_d$ Cpa$_d$ W$_d$ SRK$_d$ (Chel)WKPG-NH$_2$, <GHWSYK$_d$ (Chel)LRPG-NH$_2$, (SEQ ID NO:13)

(SEQ ID NO:14) AcK(Chel)F$_d$ CFW$_d$ KTCT-OH, AcK(Chel)DF$_d$ CFW$_d$ KTCT-OH, (SEQ ID NO:15)

(SEQ ID NO:14) AcK(Chel)F$_d$ CFW$_d$ KTCT-ol, AcK(Chel)DF$_d$ CFW$_d$ KTCT-ol, (SEQ ID NO:15)

(SEQ ID NO:16) (Chel)DF$_d$ CFW$_d$ KTCT-OH, K(Chel)DF$_d$ CFW$_d$ KTCT-ol, (SEQ ID NO:15)

(SEQ ID NO:17) K(Chel)KKF$_d$ CFW$_d$ KTCT-ol, K(Chel)KDF$_d$ CFW$_d$ KTCT-OH, (SEQ ID NO:18)

(SEQ ID NO:19) K(Chel)DSF$_d$ CFW$_d$ KTCT-OH, K(Chel)DF$_d$ CFW$_d$ KTCT-OH, (SEQ ID NO:15)

(SEQ ID NO:20) K(Chel)DF$_d$ CFW$_d$ KTCD-NH$_2$, K(Chel)DF$_d$ CFW$_d$ KTCT-NH$_2$, (SEQ ID NO:15)

(SEQ ID NO:18) K(Chel)KDF$_d$ CFW$_d$ KTCT-NHNH$_2$, AcK(Chel)F$_d$ CFW$_d$ KTCT-NHNH$_2$, (SEQ ID NO:14)

(SEQ ID NO:14) K(Chel)F$_d$ CFW$_d$ KTCT-ol, and F$_d$ CFW$_d$ KTCTK(Chel)-NH$_2$, (SEQ ID